<DOC>
	<DOCNO>NCT01605084</DOCNO>
	<brief_summary>The purpose study determine proportion subject HIV-1 RNA &lt; 50 c/mL Week 48 patient fail first line therapy contain non-nucleoside reverse transcriptase inhibitor ( NNRTI ) integrase inhibitor</brief_summary>
	<brief_title>Second-line Treatment HIV-1 With Ritonavir Boosted Atazanavir Darunavir With Optimized NRTI Backbone</brief_title>
	<detailed_description>Allocation : Randomization stratify - ATV = Atazanavir - DRV = Darunavir - RTV = Ritonavir</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>1 . Signed informed consent 2 . HIV1 infect patient viremia ( VL ≥ 500/mL ) first NNRTI INIbased cART regimen meet one two criterion : On 1st line Nonnucleoside reverse transcriptase inhibitor ( NNRTI ) Integrase inhibitor ( INI ) base Combination antiretroviral therapy ( cART ) HIV1 RNA ≥ 500 c/ML therapy least 12 week Off 1st line NNRTI INIbased Combination antiretroviral therapy ( cART ) least 2 week antiviral therapy least 4 week noncompliant first line cART without history virologic failure resistance , : HIV1 RNA ≥ 500 c/ML 3 . Fully sensitive genotype phenotype report Atazanavir/Ritonavir ( clinical cutoff 5.2 ) Darunavir/Ritonavir ( clinical cutoff range 10 90 ) 4 . At least one NRTI Lamivudine ( 3TC ) emtricitabine ( FTC ) full sensitivity ( one `` active '' NRTI ) genotype phenotype , ie , PhenoSense Genotype ( GT ) , report must provide `` sensitive '' net assessment susceptibility . An NRTI PI ( report without ritonavir ) `` partially sensitive '' net assessment consider `` fully sensitive '' 4 . Mentally able participate study 5 . Men woman ≥ 18 year old Women child bear potential engage vaginal intercourse clinically sterilize must use highly effective method birth control study 1 . Screening HIV genotype show presence baseline follow Protease inhibitor ( PI ) Mutation Patterns associate genotypic resistance Atazanavir sulfate/ Ritonavir Darunavir/Ritonavir lead exclusion : 1 . Subjects darunavir associate mutations* baseline ( *V11I , V32I , L33F , I47V , I50V , I54L , I54M , T74P , L76V , I84V L89V ) 2 . Subjects major mutation Atazanavir sulfate consist N88S 3 . Subjects 3 follow Atazanavir sulfate related mutation : D30N , M36I/V , M46I/L/T , I54V/L/T/M/A , A71V/T/I/G , G73S/A/C/T , V77I , V82A/F/T/S/I , I84V/A , N88D L90M 2 . Subjects &lt; 1 fully active NRTI PhenoSense report , lamivudine emtricitabine 3 . Diagnosed active tuberculosis 4 . Chronic hepatitis B infection 5 . Hepatitis Cpositive patient clinically stable need treatment study period 6 . Acute hepatitis 30 day prior study entry 7 . Any gastrointestinal disease surgical procedure may impact absorption study drug 8 . Intractable diarrhea within 30 day prior study entry 9 . Presence newly diagnose Human immunodeficiency virus ( HIV ) relate opportunistic infection medical condition require acute therapy time enrollment 10 . Subject 's Cushing 's syndrome 11 . Untreated hypothyroidism hyperthyroidism 12 . Recent therapy agent significant systemic myelosuppressive , neurotoxic , pancreatotoxic , hepatotoxic cytotoxic potential within 3 month study start 13 . Subject 's obstructive liver disease 14 . Active alcohol illegal substance use 15 . Inability swallow capsule 16 . Active peripheral neuropathy 17 . Presence cardiomypathy significant cardiovascular disease 18 . Known , clinically significant cardiac conduction system disease 19 . Physical Laboratory Test Findings : Moderate severe hepatic insufficiency Screening laboratory value follow : T4 &lt; 4mcg/dL &gt; 11mcg/dL and/or Thyroidstimulating hormone ( TSH ) &lt; 0.5mU/L &gt; 5.0mU/L Calculated creatinine clearance &lt; 60 cc/min Hemoglobin &lt; 8.0 g/dL Total serum lipase ≥ 1.4 time upper limit normal ( ULN ) Liver enzymes [ Aspartate transaminase ( AST ) , Alanine transaminase ( ALT ) ] ≥ 5 time ULN Alkaline phosphatase &gt; 5 time ULN Platelets &lt; 50,000 cells/mm3 Positive blood screen hepatitis B surface antigen ( HBsAg ) Total serum bilirubin ≥ 1.5 time ULN 20 . Allergies Adverse Drug Reaction : Previously demonstrate hypersensitivity component atazanavir experimental agent study Darunavir contains sulfonamide moiety . Darunavir use caution patient know sulfonamide allergy History allergy atazanavir , ritonavir , darunavir History allergy NRTIs include NRTI backbone option study History clinically relevant severe drug reaction 21 . Sex Reproductive Status : Women positive pregnancy test enrollment prior study drug administration Women become pregnant study take offprotocol Women use prohibited contraceptive method Women breastfeed 22 . Other Exclusion Criteria Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment wither psychiatric physical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>